1. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia
by Robin Foà, Antonella Vitale, Marco Vignetti, Giovanna Meloni, Anna Guarini, Maria Stefania De Propris, Loredana Elia, Francesca Paoloni, Paola Fazi, Giuseppe Cimino, Francesco Nobile, Felicetto Ferrara, Carlo Castagnola, Simona Sica, Pietro Leoni, Eliana Zuffa, Claudio Fozza, Mario Luppi, Anna Candoni, Ilaria Iacobucci, Simona Soverini, Franco Mandelli, Giovanni Martinelli, Michele Baccarani, and
Blood
Volume 118(25):
December 15, 2011
©2011 by American Society of Hematology

2. BCR-ABL transcript levels during dasatinib therapy.
BCR-ABL transcript levels during dasatinib therapy. (A) All patients. (B) Patients who subsequently relapsed (red) or remained in remission at the last follow-up (blue). (C) Patients with p190 (red) or p210 (blue) forms of BCR-ABL. For display purposes, undetectable BCR-ABL transcript levels are plotted at
Robin Foà et al. Blood 2011;118:
©2011 by American Society of Hematology

3. Survival curves. Survival curves. (A) OS. (B) DFS from day 85.
Robin Foà et al. Blood 2011;118:
©2011 by American Society of Hematology

4. DFS according to BCR-ABL transcript reduction during dasatinib treatment.
DFS according to BCR-ABL transcript reduction during dasatinib treatment. (A) BCR-ABL levels < 10−3 at day 22 (n = 10) versus patients who never achieved levels < 10−3 during dasatinib induction treatment (n = 7). (B) BCR-ABL levels < 10−3 (n = 25) or ≥ 10−3 (n = 23) at day 85.
Robin Foà et al. Blood 2011;118:
©2011 by American Society of Hematology

5. DFS according to immunophenotype evaluation at day 85.
Robin Foà et al. Blood 2011;118:
©2011 by American Society of Hematology